Tempus: Genomics, Big Data, and AI
from Nanalyze Hosted by Nanalyze
AI stocks are still taking the world by storm, so when an "AI stock" has an IPO, we're bound to cover it. Tempus is a precision medicine startup seeking $100M in an IPO that could launch this year. The proposed IPO valuation will be around $8 billion. Tempus calls itself an AI stock because it is one. The company leverages AI and data to improve healthcare. Tempus's technology can help with predicting treatment effectiveness, identifying clinical trials, and making informed treatment decisions. Watch our video to see our thoughts on Tempus and the current AI hype. Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/VbUh2_3D9dE.
Embed this episode
No transcript yet.